Azura Ophthalmics
Tel Aviv, Israel· Est.
Israeli biotech creating keratolytic eye‑drop therapies for unmet ocular surface diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli biotech creating keratolytic eye‑drop therapies for unmet ocular surface diseases.
OphthalmologyOcular Surface Disease
Technology Platform
First‑in‑class ophthalmic keratolytics that target hyperkeratinized lid margin and ocular surface epithelium to treat underlying pathology.
Opportunities
Significant unmet need in ocular surface diseases and a large, growing market for novel therapies beyond anti‑inflammatory agents.
Risk Factors
Technical risk of translating keratolytic chemistry into safe ocular formulations and regulatory uncertainty for a new therapeutic class.
Competitive Landscape
Competes with existing dry‑eye and ocular surface treatments (e.g., lifitegrast, cyclosporine) but differentiates through a keratolytic mechanism targeting epithelial keratinization.